Mode
Text Size
Log in / Sign up
N/A N=213 Randomized Single-blind Treatment

Mobile Diabetes Management

Diabetes

Enrolled (actual)
213
Serious AEs
0.0%
Results posted
Mar 2018
Primary outcome: Primary: HBA1c at One Year — 8.5; 7.7; 7.9; 7.9 percentage of HbA1c — p=0.027

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Tailored Patient Intervention (Device); Patient-physician intervention (Device); Patient and PCP intervention with analyzed data (Device)
Age
Adult · 18+ yrs
Sex
All
Sponsor
University of Maryland, Baltimore
Primary completion
Aug 2010

Outcome Measures

OutcomeResultp-value
PRIMARY
HBA1c at One Year
8.5; 7.7; 7.9; 7.9 0.027 sig

Summary

The Mobile Diabetes Intervention Study trial is evaluating a diabetes coaching system, using mobile phones and patient/ physician internet portals to allow patient-specific treatment and communication by their primary care physician. We hypothesize that timely information provided to patients and their physicians can result in reduction of A1c over 1 year.

Eligibility Criteria

Inclusion Criteria

  • Type 2 diabetic [patient]
  • A1c equal to or greater than 7.5 [patient]
  • 18-64 years of age at time of recruitment [patient]
  • Access to the internet (does not need to be at their home, elsewhere is fine e.g. work) [patient]
  • E-mail account [patient]
  • Must speak English [patient]

Exclusion Criteria

  • No insulin pump [patient]
  • No current alcohol or drug abuse- must be sober 1 year [patient]
  • Not currently pregnant [patient]
  • No terminal diagnosis [patient]
  • No dementia or Alzheimer's [patient]
  • No active chemotherapy [patient]
  • No significant hearing impairment [patient]
  • Poorly corrected vision that would impede use of phone [patient]
  • No mute or aphasia [patient]
  • No diagnosis of schizophrenia, bipolar disorder, or major psychosis [patient]
  • No Medicaid or Medicare
  • No uninsured
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01107015). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search